ISSN: 0169-5002
Journal Home
Journal Guideline
Lung Cancer Q1 Unclaimed
Lung Cancer is a journal indexed in SJR in Oncology and Cancer Research with an H index of 148. It has an SJR impact factor of 1,761 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 1,761.
Lung Cancer focuses its scope in these topics and keywords: lung, cancer, cell, nonsmall, combination, treatment, chemotherapy, egfr, patients, coalmining, ...
Type: Journal
Type of Copyright:
Languages: English
Open Access Policy:
Type of publications:
Publication frecuency: -
- €
Inmediate OANPD
Embargoed OA- €
Non OAMetrics
1,761
SJR Impact factor148
H Index228
Total Docs (Last Year)892
Total Docs (3 years)9217
Total Refs3811
Total Cites (3 years)788
Citable Docs (3 years)4.16
Cites/Doc (2 years)40.43
Ref/DocOther journals with similar parameters
Molecular Cancer Q1
Journal of Thoracic Oncology Q1
JAMA oncology Q1
Cancer Discovery Q1
Journal of Hematology and Oncology Q1
Compare this journals
Aims and Scope
Best articles by citations
248 High incidence of isolated brain metastases (CNSMets) following complete response (CR) in advanced non-small cell lung cancer (NSCLC): A new challenge
View moreCooking oil fumes and risk of lung cancer in women in rural Gansu, China
View morePrognostic value of the serum tumour markers Cyfra 21-1 and tissue polypeptide antigen in malignant mesothelioma
View moreDocetaxel and carboplatin as second-line chemotherapy for metastatic non-small cell lung cancer
View moreA dose escalation study of topotecan in combination with epirubicin in pretreated patients with small-cell lung cancer
View more78 A phase II study of paclitaxel (Taxol®) and ifosfamide (Holoxan®) in advanced non-small cell lung cancer
View moreHigh cyclin E and low p27/Kip1 expressions are potentially poor prognostic factors in lung adenocarcinoma patients
View moreCo-expression of epidermal growth factor receptor and transforming growth factor-a is independent of ras mutations in lung adenocarcinoma
View moreCriteria of functional and oncological operability in surgery for lung cancer: A multicenter study
View moreReply to Grannis
View moreWhy are bronchopulmonary carcinoid tumours unique?
View more127 Spirometric control following vinca alkaloids in patients receiving mitomycin
View moreGemcitabine (GEM) and carboplatin (CBDCA) versus cisplatin (CDDP) and vinblastine (VLB) in advanced non-small-cell lung cancer (NSCLC) stages III and IV: a phase III randomised trial
View more168 A pilot study of high dose chemotherapy and irradiation with NEUPOGEN (G-CSF) in limited disease small cell lung cancer (SCLC)
View more250 Phase III study of the value of adding cisplatin (C) and etoposide (E) to radiation in patients with locally advanced squamous cell carcinoma of the lung (SQCL). A multicentric swedish study of 302 patients
View moreOverview of lung cancer screening and early cancer detection
View moreMetastasis to the penis in a patient with squamous cell carcinoma of the lung with a review of reported cases
View moreA short radiotherapy course for locally advanced non-small cell lung cancer (NSCLC). Effective palliation and patients' convenience
View moreHigh-resolution computed tomography of bronchioloalveolar cell carcinoma
View moreGemcitabine plus vinorelbine in stage IIIB or IV non-small cell lung cancer (NSCLC): a multicentre phase II clinical trial
View more63 Navelbine (NVB), and fractionated doses of cisplatin (CDDP) - 20 mg/m2/5 days - in the management of advanced non-small cell lung cancer: An overview of 3 phase II trials
View moreCorrelation of p53 oncoprotein expression with chemotherapy response in small cell lung carcinomas
View more275 Anti-cachectic effect of clarithromycin in inoperable non-small cell lung cancer patients
View moreDiagnosis and Treatment of Lung Cancer. An Evidence-Based Guide for the Practicing Clinician
View more
Comments